oai:pubmedcentral.nih.gov:8135...
Oxford University Press
Oxford University Press Public Health Emergency Collection
2021
1/13/2023
Background/Aims To quantify the risk of death among people with vasculitis during the UK 2020 COVID-19 epidemic compared with baseline risk, risk during annual influenza seasons and risk of death in the general population during COVID-19.
Methods We performed a cohort study using data from the National Congenital Anomaly and Rare Disease Registration Service (NCARDRS) under their legal permissions (CAG 10-02(d)/2015).
Coded diagnoses for vasculitis (ANCA-associated vasculitis, Takayasu arteritis, Behçet's disease, and giant cell arteritis) were identified from Hospital Episode Statistics from 2003 onwards.
Previous coding validation work demonstrated a positive predictive value >85%.
The main outcome measure was age-standardised mortality rates (ASMRs) for all-cause death.
ONS published data were used for general population mortality rates.
Results We identified 55,110 people with vasculitis (median age 74.9 (IQR 64.1-82.7) years, 68.0% female) alive 01 March 2020.
During March-April 2020, 892 (1.6%) died of any cause.
The crude mortality rate was 9773.0 (95% CI 9152.3-10,435.9) per 100,000 person-years.
The ASMR was 2567.5 per 100,000 person-years, compared to 1361.1 (1353.6-1368.7) in the general population (see table).
The ASMR in March-April 2020 was 1.4 times higher than the mean ASMR for March-April 2015-2019 (1965.6).
The increase in deaths during March-April 2020 occurred at a younger age than in the general population.
We went on to investige the effect of previous influenza seasons.
The 2014/15 season saw the greatest excess all-cause mortality nationally in recent years, and there were 624 deaths in 38,888 people (6472.5 person-years) with vasculitis in our data (crude mortality rate 9640.8 (8913.3-10427.7); The ASMR was 2657.6, which was marginally higher than the ASMR among people with vasculitis recorded during March-April 2020 during the COVID-19 pandemic.
Conclusion People with vasculitis are at increased risk of death during circulating COVID-19 and influenza epidemics.
The ASMR among people with vasculitis was high both during the 2014/15 influenza season and during the first wave of the COVID-19 epidemic.
COVID-19 vaccination and annual influenza vaccination for people with vasculitis are both important, regardless of patient age.
Disclosure M. Rutter: None.
P.C. Lanyon: Grants/research support; PCL has received funding for research from Vifor Pharma.
.
M.J. Grainge: None.
R.B. Hubbard: None.
E.J. Peach: Grants/research support; EJP has received funding for research from Vifor Pharma.
M. Bythell: None.
J. Aston: None.
S. Stevens: None.
F.A. Pearce: Grants/research support; FAP has received funding for research from Vifor Pharma.
.
Rutter, Megan,Lanyon, Peter C,Grainge, Matthew J,Hubbard, Richard B,Peach, Emily J,Bythell, Mary,Aston, Jeanette,Stevens, Sarah,Pearce, Fiona A, 2021, O24 Risk of death during the 2020 UK COVID-19 epidemic and annual influenza seasons among people with vasculitis compared to the general population: a whole-population study using data from the NDRS and the RECORDER project, Oxford University Press